K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/- mast cells

Journal of Immunology

Volumn 178, Issue 4, 2007, Pages 2527-2534

  Khalaf, Waleed F ^a   Yang, Feng Chun ^a   Chen, Shi ^a   White, Hilary ^a   Bessler, Waylan ^a   Ingram, David A ^a   Clapp, D Wade ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROFIBROMIN; PROTEIN KINASE B; RAS PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; LIVER; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; ONCOGENE C KIT; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL;

EID: 33846916195     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.4.2527     Document Type: Article

References (83)

1. Bourne, H. R., D. A. Sanders, and F. McCormick. 1990. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348: 125-132.
2. Bourne, H. R., D. A. Sanders, and F. McCormick. 1991. The GTPase superfamily: conserved structure and molecular mechanism. Nature 349: 117-127.
3. Hall, A. 1990. The cellular functions of small GTP-binding proteins. Science 249: 635-640.
4. Hall, A. 1992. Signal transduction through small GTPases-a tale of two GAPs. Cell 69: 389-391.
5. Satoh, T., M. Nakafuku, A. Miyajima, and Y. Kaziro. 1991. Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc. Natl. Acad. Sci. USA 88: 3314-3318.
6. Hill, C. S., and R. Treisman. 1995. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80: 199-211.
7. Bar-Sagi, D., and A. Hall. 2000. Ras and Rho GTPases: a family reunion. Cell 103: 227-238.
8. Ehrhardt, A., G. R. Ehrhardt, X. Guo, and J. W. Schrader. 2002. Ras and relatives: job sharing and networking keep an old family together. Exp. Hematol 30: 1089-1106.
9. Scheele, J. S., D. Ripple, and M. Lubbert. 2000. The role of ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation. Cell Mol. Life Sci. 57: 1950-1963.
10. Rebollo, A., and A. C. Martinez. 1999. Ras proteins: recent advances and new functions. Blood 94: 2971-2980.
11. Macaluso, M., G. Russo, C. Cinti, V. Bazan, N. Gebbia, and A. Russo. 2002. Ras family genes: an interesting link between cell cycle and cancer. J. Cell Physiol. 192: 125-130.
12. Bos, J. L. 1989. ras Oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689.
13. Esteban, L. M., C. Vicario-Abejon, P. Fernandez-Salguero, A. Fernandez-Medarde, N. Swaminathan, K. Yienger, E. Lopez, M. Malumbres, R. McKay, J. M. Ward, A. Pellicer, and E. Santos. 2001. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell. Biol. 21: 1444-1452.
14. Umanoff, H., W. Edelmann, A. Pellicer, and R. Kucherlapati. 1995. The murine N-ras gene is not essential for growth and development. Proc. Natl. Acad. Sci. USA 92: 1709-1713.
15. Johnson, L., D. Greenbaum, K. Cichowski, K. Mercer, E. Murphy, E. Schmitt, R. T. Bronson, H. Umanoff, W. Edelmann, R. Kucherlapati, and T. Jacks. 1997. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11: 2468-2481.
16. Koera, K., K. Nakamura, K. Nakao, J. Miyoshi, K. Toyoshima, T. Hatta, H. Otani, A. Aiba, and M. Katsuki. 1997. K-ras is essential for the development of the mouse embryo. Oncogene 15: 1151-1159.
17. Bar-Sagi, D. 2001. A Ras by any other name. Mol. Cell. Biol. 21: 1441-1443.
18. Hancock, J. F., A. I. Magee, J. E. Childs, and C. J. Marshall. 1989. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57: 1167-1177.
19. Apolloni, A., I. A. Prior, M. Lindsay, R. G. Parton, and J. F. Hancock. 2000. H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol. Cell. Biol. 20: 2475-2487.
20. Prior, I. A., and J. F. Hancock. 2001. Compartmentalization of Ras proteins. J. Cell Sci. 114: 1603-1608.
21. Chiu, V. K., T. Bivona, A. Hach, J. B. Sajous, J. Silletti, H. Wiener, R. L. Johnson, 2nd, A. D. Cox, and M. R. Philips. 2002. Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 4: 343-350.
22. Hancock, J. F. 2003. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4: 373-384.
23. Walsh, A. B., and D. Bar-Sagi. 2001. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J. Biol. Chem. 276: 15609-15615.
24. Voice, J. K., R. L. Klemke, A. Le, and J. H. Jackson. 1999. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J. Biol. Chem. 274: 17164-17170.
25. Yan, J., S. Roy, A. Apolloni, A. Lane, and J. F. Hancock. 1998. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. 273: 24052-24056.
26. Wolfman, J. C., T. Palmby, C. J. Der, and A. Wolfman. 2002. Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38. Mol. Cell. Biol. 22: 1589-1606.
27. Wolfman, J. C., and A. Wolfman. 2000. Endogenous c-N-Ras provides a steady-state anti-apoptotic signal. J. Biol. Chem. 275: 19315-19323.
28. Boguski, M. S., and F. McCormick. 1993. Proteins regulating Ras and its relatives. Nature 366: 643-654.
29. Menon, A. G., K. M. Anderson, V. M. Riccardi, R. Y. Chung, J. M. Whaley, D. W. Yandell, G. E. Farmer, R. N. Freiman, J. K. Lee, F. P. Li, et al. 1990. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. USA 87: 5435-5439.
30. Xu, G. F., P. O'Connell, D. Viskochil, R. Cawthon, M. Robertson, M. Culver, D. Dunn, J. Stevens, R. Gesteland, R. White, and R. Weiss. 1990. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62: 599-608.
31. Viskochil, D., A. M. Buchberg, G. Xu, R. M. Cawthon, J. Stevens, R. K. Wolff, M. Culver, J. C. Carey, N. G. Copeland, and N. A. Jenkins. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62: 187-192.
32. Wallace, M. R., D. A. Marchuk, L. B. Andersen, R. Letcher, H. M. Odeh, A. M. Saulino, J. W. Fountain, A. Brereton, J. Nicholson, and A. L. Mitchell. 1990. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249: 181-186.
33. Marchuk, D. A., A. M. Saulino, R. Tavakkol, M. Swaroop, M. R. Wallace, L. B. Andersen, A. L. Mitchell, D. H. Gutmann, M. Boguski, and F. S. Collins. 1991. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 11: 931-940.
34. Gutmann, D. H., and F. S. Collins. 1993. The neurofibromatosis type! gene and its protein product, neurofibromin. Neuron 10: 335-343.
35. Martin, G. A., D. Viskochil, G. Bollag, P. C. McCabe, W. J. Crosier, H. Haubruck, L. Conroy, R. Clark, P. O'Connell, R. M. Cawthon, M. A. Innis, and F. McCormick. 1990. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63: 843-849.
36. +/- Cells. J. Biol. Chem. 276: 7240-7245.
37. +/- mast cells. J. Clin. Invest. 112: 1851-1861.
38. Hiatt, K., D. A. Ingram, H. Huddleston, D. F. Spandau, R. Kapur, and D. W. Clapp. 2004. Loss of the Nf1 tumor suppressor gene decreases Fas antigen expression in myeloid cells. Am. J. Pathol 164: 1471-1479.
39. 1ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69: 265-273.
40. Cichowski, K., T. S. Shih, E. Schmitt, S. Santiago, K. Reilly, M. E. McLaughlin, R. T. Bronson, and T. Jacks. 1999. Mouse models of tumor development in neurofibromatosis type 1. Science 286: 2172-2176.
41. McLaughlin, M. E., and T. Jacks. 2002. Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. Cancer Cell 1: 408-410.
42. Hirota, S., S. Nomura, H. Asada, A. Ito, E. Morii, and Y. Kitamura. 1993. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch. Pathol. Lab. Med. 117: 996-999.
43. Zhu, Y., P. Ghosh, P. Charnay, D. K. Burns, and L. F. Parada. 2002. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296: 920-922.
44. Coussens, L. M., and Z. Werb. Inflammatory cells and cancer: think different! J. Exp. Med. 193:F23-26, 2001.
45. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
46. Coussens, L. M., C. L. Tinkle, D. Hanahan, and Z. Werb. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
47. Coussens, L. M., and Z. Werb. 1996. Matrix metalloproteinases and the development of cancer. Chem. Biol. 3: 895-904.
48. Boesiger, J., M. Tsai, M. Maurer, M. Yamaguchi, L. F. Brown, K. P. Claffey, H. F. Dvorak, and S. J. Galli. 1998. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fcε receptor I expression. J. Exp. Med. 188: 1135-1145.
49. Galli, S. J., J. Kalesnikoff, M. A. Grimbaldeston, A. M. Piliponsky, C. M. Williams, and M. Tsai. 2005. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23: 749-786.
50. ras and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin deficient mast cells in vivo and in vitro. J. Exp. Med. 194: 57-69.
51. Ingram, D. A., F. C. Yang, J. B. Travers, M. J. Wenning, K. Hiatt, S. New, A. Hood, K. Shannon, D. A. Williams, and D. W. Clapp. 2000. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J. Exp. Med. 191: 181-188.
52. Leon, J., I. Guerrero, and A. Pellicer. 1987. Differential expression of the ras gene family in mice. Mol. Cell. Biol. 7: 1535-1540.
53. Pells, S., M. Divjak, P. Romanowski, H. Impey, N. J. Hawkins, A. R. Clarke, M. L. Hooper, and D. J. Williamson. 1997. Developmentally-regulated expression of murine K-ras isoforms. Oncogene 15: 1781-1786.
54. ras in normal and malignant human tissues: lack of association with proliferation and malignancy. Proc. Natl. Acad. Sci. USA 84: 3234-3238.
55. Furth, M. E., T. H. Aldrich, and C. Cordon-Cardo. 1987. Expression of ras proto-oncogene proteins in normal human tissues. Oncogene 1: 47-58.
56. Muller, R., D. J. Slamon, E. D. Adamson, J. M. Tremblay, D. Muller, M. J. Cline, and I. M. Verma. 1983. Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol. Cell. Biol. 3: 1062-1069.
57. ras GTPase-activating protein. Proc. Natl. Acad. Sci. USA 89: 1587-1591.
58. Meininger, C., H. Yano, R. Rottapel, A. Bernstein, K. Zsebo, and B. Zetter. 1992. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79: 958-963.
59. Iemura, A., M. Tsai, A. Ando, B. Wershil, and S. Galli. 1994. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am. J. Pathol 144: 321-328.
60. Galli, S. J., M. Tsai, and B. K. Wershil. 1993. The c-kit receptor, stem cell factor, and mast cells. Am. J. Pathol. 142: 965-974.
61. Costa, J. J., G. D. Demetri, T. J. Harrist, A. M. Dvorak, D. F. Hayes, E. A. Merica, D. M. Menchaca, A. J. Gringeri, L. B. Schwartz, and S. J. Galli. 1996. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J. Exp. Med. 183: 2681-2686.
62. Tsai, M., L.-S. Shih, Newlands, G., F. J., TAKEISHI T, K. Langley, K. Zsebo, H. Miller, Geissler, E. N., and S. Galli. 1991. c-kit ligand, SCF, induces the development of connective tissue-type and mucosal mast cells in vivo: analysis by anatomical distribution, histochemistry, and protease phenotype. J. Exp. Med. 174: 125-131.
63. Yee, N. S., I. Paek, and P. Besmer. 1994. Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice. J. Exp. Med. 179: 1777-1787.
64. Huddleston, H., B. Tan, F. C. Yang, M. J. Wenning, A. Orazi, M. C. Yoder, L. C. Cantley, R. Kapur, and D. A. Ingram. 2003. A functional p85α gene is required for normal murine fetal erythropoiesis. Blood 102: 142-145.
65. L expression while mediating survival and actin function in primary mast cells. Immunity 12: 557-568.
66. Yang, F. C., S. J. Atkinson, Y. Gu, J. B. Borneo, A. W. Roberts, Y. Zheng, J. Pennington, and D. A. Williams. 2001. Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. Proc. Natl. Acad. Sci. USA 98: 5614-5618.
67. 4 integrin-mediated signals on class IA PI-3kinase and the Rac pathway in regulating integrin-directed migration in mast cells. Blood 101: 4725-4732.
68. Tara S. Y., M. Tsai, J. N. Snouwaert, J. Kalesnikoff, D. Scherrer, S. Nakae, D. Chatterjea, D. M. Bouley, and S. J. Galli. 2004. RabGEF1 is a negative regulator of mast cell activation and skin inflammation. Nat. Immunol. 5: 844-852.
69. v mice and their increase by bone marrow transplantation. Blood 52: 447-452.
70. Galli, S. J. 1993. New concepts about the mast cell. N. Engl. J. Med. 328: 257-265.
71. Galli, S. J., M. Maurer, and C. S. Lantz. 1999. Mast cells as sentinels of innate immunity. Curr. Opin. Immunol. 11: 53-59.
72. Coussens, L. M., W. Raymond, G. Bergers, M. Webster, O. Behrendtsen, W. Z., G. Caughey, and D. Hanahan. 1999. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13: 1382-1397.
73. Timokhina, I., H. Kissel, G. Stella, and P. Besmer. 1998. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J. 17: 6250-6262.
74. Kalesnikoff, J., E. J. Rios, C. C. Chen, S. Nakae, B. A. Zabel, E. C. Butcher, M. Tsai, S. Y. Tam, and S. J. Galli. 2006. RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells. Proc. Natl. Acad. Sci. USA 103: 2659-2664.
75. Dasgupta, B., W. Li, A. Perry, and D. H. Gutmann. 2005. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 65: 236-245.
76. Lancet, J. E., and J. E. Karp. 2003. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102: 3880-3889.
77. Morgan, M. A., A. Ganser, and C. W. Reuter. 2003. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia 17: 1482-1498.
78. Adjei, A. A. 2001. Blocking oncogenic Ras signaling for cancer therapy, J. Natl. Cancer Inst. 93: 1062-1074.
79. Mahgoub, N., B. R. Taylor, M. Gratiot, N. E. Kohl, J. B. Gibbs, T. Jacks, and K. M. Shannon. 1999. In vitro and in vivo effects of a famesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood 94: 2469-2464.
80. Prendergast, G. C. 2000. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr. Opin. Cell Biol. 12: 166-173.
81. V12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc. Natl. Acad. Sci. USA 93: 4454-4458.
82. Fiordalisi, J. J., R. L. Johnson, 2nd, C. A. Weinbaum, K. Sakabe, Z. Chen, P. J. Casey, and A. D. Cox. 2003. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors. J. Biol. Chem. 278: 41718-41727.
83. Morgan, M. A., J. Wegner, E. Aydilek, A. Ganser, and C. W. Reuter. 2003. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia 17: 1508-1520.